Company intelligence / Profile preview

CILA Therapeutics

Boston, Massachusetts, United Statescilatx.com ↗

Ownership: Private
Employees: ~10
Development stage: Preclinical

Overview

CILA Therapeutics has developed a proprietary inhaled therapy platform aimed at clearing persistent airway mucus plugs—a major unmet need in obstructive airway diseases. The company’s lead program targets rare genetic and chronic respiratory conditions such as Primary Ciliary Dyskinesia. As of the latest updates, the company has built a pipeline of five programs but has not yet reported late-stage clinical results

Therapeutic areas: PulmonologyRare Diseases
Modalities: OligonucleotidesmRNADNA therapeuticsdry powder microsphere inhaled formulations
Industry: Biotech

Drug pipeline

1 asset

CIL-05

Pre-clinical

Indications: Primary ciliary dyskinesia

Beyond the preview

Go deeper on CILA Therapeutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on CILA Therapeutics.